Get the Stockscreener App
169.81
1.26%
-2.2347
Neurocrine Biosciences Inc stock is traded at $169.81, with a volume of 20,609.
It is down -1.26% in the last 24 hours and up +6.50% over the past month.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
See More
Previous Close:
$172.04
Open:
$172.04
24h Volume:
20,609
Relative Volume:
0.02
Market Cap:
$17.07B
Revenue:
$3.10B
Net Income/Loss:
$668.60M
P/E Ratio:
26.11
EPS:
6.5044
Net Cash Flow:
$831.30M
1W Performance:
-4.69%
1M Performance:
+6.50%
6M Performance:
+27.39%
1Y Performance:
+29.44%
1-Day Range:
$169.44
$172.43
1-Week Range:
$169.04
$181.18
52-Week Range:
$122.14
$181.18
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Name
Neurocrine Biosciences Inc
Sector
Phone
(858) 617-7600
Address
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
169.78 | 17.51B | 3.10B | 668.60M | 831.30M | 6.5044 |
TAK
Takeda Pharmaceutical Co Adr
|
16.32 | 52.66B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.65 | 43.42B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.70 | 37.47B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
75.69 | 31.61B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
522.18 | 22.73B | 3.17B | 1.29B | 1.01B | 27.09 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-26 | Initiated | Wolfe Research | Outperform |
| Jan-08-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-21-25 | Initiated | Citigroup | Buy |
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-10-25 | Initiated | Goldman | Buy |
| Apr-15-25 | Upgrade | Needham | Hold → Buy |
| Apr-14-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-29-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-24-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-13-23 | Resumed | Citigroup | Neutral |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-21-23 | Reiterated | Mizuho | Neutral |
| Jul-24-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Jul-06-23 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
| May-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-30-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-14-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Oct-11-22 | Initiated | UBS | Buy |
| Sep-26-22 | Initiated | Wells Fargo | Equal Weight |
| Jun-06-22 | Resumed | Jefferies | Buy |
| Mar-03-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Feb-25-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-18-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-21 | Initiated | BMO Capital Markets | Underperform |
| Nov-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-14-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-23-21 | Resumed | Needham | Hold |
| Aug-06-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| May-18-21 | Resumed | Goldman | Neutral |
| May-06-21 | Upgrade | Barclays | Equal Weight → Overweight |
| Feb-02-21 | Initiated | Raymond James | Outperform |
| Sep-30-20 | Initiated | The Benchmark Company | Hold |
| Aug-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-29-20 | Downgrade | Goldman | Buy → Neutral |
| Jun-09-20 | Initiated | Wedbush | Outperform |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-24-20 | Initiated | William Blair | Outperform |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Feb-05-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-13-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Aug-07-19 | Initiated | RBC Capital Mkts | Outperform |
| Jul-16-19 | Initiated | Oppenheimer | Outperform |
| Jun-05-19 | Initiated | Guggenheim | Neutral |
| May-21-19 | Initiated | Credit Suisse | Outperform |
| Apr-22-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Feb-06-19 | Reiterated | BofA/Merrill | Buy |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-13-18 | Initiated | Goldman | Buy |
| Nov-21-18 | Initiated | Canaccord Genuity | Buy |
View All
Neurocrine Biosciences Inc Stock (NBIX) Latest News
Can Neurocrine (NBIX) Run Higher on Rising Earnings Estimates? - Yahoo Finance
Neurocrine Price Target Raised to $200.00/Share From $155.00 by Truist Securities - Moomoo
Form 4 Neurocrine Biosciences Inc For: 13 July By Investing.com - Investing.com Nigeria
Neurocrine Biosciences chief legal officer sells $1.79m in stock By Investing.com - Investing.com Nigeria
[Form 4] NEUROCRINE BIOSCIENCES INC Insider Trading Activity - Stock Titan
Neurocrine Biosciences chief legal officer sells $1.79m in stock - Investing.com
Neurocrine Biosciences (NBIX) officer exercises options, sells 4,367 shares - Stock Titan
NBIX Maintained by BMO Capital -- Price Target Raised to $170 - GuruFocus
Truist raises Neurocrine Bio stock price target on pipeline potential - Investing.com
Truist raises Neurocrine Bio stock price target on pipeline potential By Investing.com - Investing.com Australia
Wedbush Lifts Price Target on Neurocrine Biosciences to $185 From $176, Keeps Outperform Rating - Moomoo
Reasons why investors should consider betting on Neurocrine stock - MSN
Neurocrine Biosciences (NBIX) Posts Strong Q1 Results, Is More Upside Still Left? - simplywall.st
Neurocrine Biosciences Inc (NASDAQ:NBIX) Scores High in Affordable Growth Screen - ChartMill
NEUROCRINE BIOSCIENCES INC (NBIX) Stock Chart - ChartMill
Form 144 NEUROCRINE BIOSCIENCES For: 10 July By Investing.com - Investing.com South Africa
Form 144 NEUROCRINE BIOSCIENCES For: 10 July - Investing.com India
[144] NEUROCRINE BIOSCIENCES INC SEC Filing - Stock Titan
3 Reasons Why Growth Investors Shouldn't Overlook Neurocrine (NBIX) - Yahoo Finance
Neurocrine Shares Hit Highs on Sales Spike, Strong Pipeline - FXEmpire
Neurocrine Biosciences Insider Sold Shares Worth $2,603,112, According to a Recent SEC Filing - Moomoo
Did Neurocrine’s (NBIX) CRENESSITY Push Into Infants Just Recast Its Rare-Disease Strategy? - simplywall.st
Neurocrine Biosciences chief regulatory officer sells $2.6m stock By Investing.com - Investing.com India
Neurocrine Biosciences chief regulatory officer sells $2.6m stock - Investing.com
Form 4 Neurocrine Biosciences Inc For: 9 July By Investing.com - Investing.com South Africa
Neurocrine (NBIX) officer sells 14,571 shares under Rule 10b5-1 plan - Stock Titan
Form 144 NEUROCRINE BIOSCIENCES For: 9 July By Investing.com - Investing.com Nigeria
10,000 NBIX shares listed for sale; recent Darin Lippoldt 10b5-1 trades (NBIX) - Stock Titan
Neurocrine Biosciences | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Neurocrine's July 30 earnings call is scheduled for 4:30 p.m. ET - Stock Titan
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2026 Financial Results - The Independent Record
Neurocrine Biosciences stock stays supported by a growing movement disorder portfolio - AD HOC NEWS
ETFs Investing in Neurocrine Biosciences, Inc. Stocks - TradingView
Neurocrine Biosciences (NBIX) Stock Looks Reasonable After Its 90% Run - Sahm
Neurocrine Biosciences (NBIX) Stock Looks Fair On Earnings But Pricey Versus Biotechs - Yahoo Finance
Neurocrine Biosciences (NBIX) Could Be 8% Undervalued Following New Phase 2 Study - Yahoo Finance
Neurocrine Biosciences (NBIX) Starts Phase 2 CAH Study In Children Under 4 - Yahoo Finance
Neurocrine (NBIX) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
Tardive Dyskinesia Market to Grow Rapidly at a CAGR of 8.1% During the Forecast Period (2026-2036) | DelveInsight - Yahoo Finance
Ovid Therapeutics: Norrett Most Recently Served as Chief Business Officer at Soleno Therapeutics, Where He Led Company's Acquisition by Neurocrine Biosciences >OVID - Moomoo
Neurocrine Biosciences outlines its neurology focus as a mid-cap biotech name - AD HOC NEWS
Insider option exercise and 10b5-1 sales at NBIX (NBIX) - Stock Titan
Neurocrine Biosciences Presents New Data Highlighting Functional and Socio-emotional Improvements with INGREZZA® (valbenazine) Capsules in Individuals with Tardive Dyskinesia and Intellectual and Developmental Disabilities - AOL.com
Neurocrine Biosciences stock hits all-time high at 176.1 USD By Investing.com - Investing.com Nigeria
Neurocrine Biosciences stock hits all-time high at 176.1 USD - Investing.com
Neurocrine Biosciences stock and its role in neurological treatments - AD HOC NEWS
RBC Capital Adjusts Neurocrine Biosciences Price Target to $195 From $183, Maintains Outperform Rating - Moomoo
Reasons Why Investors Should Consider Betting on Neurocrine Stock - Yahoo Finance
Neurocrine Biosciences, Inc. (NBIX): Analyst Consensus and Growth Potential with a 12% Upside - DirectorsTalk Interviews
Enterprise value to EBIT forward of Neurocrine Biosciences, Inc. – NASDAQ:NBIX - TradingView
Neurocrine Biosciences Inc Stock (NBIX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.71%
0.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):